Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
CJC-1295 is a synthetic analog of GHRH that has been modified to significantly extend its biological half-life
Reduces glucagon production (a hormone that raises blood sugar)
These mediators extend beyond adipose depots, propagating systemic inflammation, endothelial dysfunction, and oxidative stress
The effect of glucagon-like peptide 1 on cardiovascular risk
This was the case in our pre-registered primary analysis (where we report a significant group effect across groups of participants with type-2 diabetes, on and off semaglutide, and BMI-matched and -unmatched healthy controls, which numerically show decreasing acceptance bias), and in our exploratory dimensional finding that increasing risk of diabetes is associated with lower acceptance bias across study groups
These early studies focused on safety, tolerability, pharmacokinetics, and initial pharmacodynamic effects in healthy volunteers and patients with obesity or type 2 diabetes
